MTOR and mature T-cell and NK-cell non-Hodgkin lymphoma: Aberrant activation of the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway contributes to tumorigenesis, metastasis, chemoresistance, and poor outcomes in PTCL patients (8).